Fusion Protein

Fusion Protein designates recombinant molecules combining functional domains from multiple proteins into single polypeptide chains, creating therapeutic agents with enhanced properties, novel functionalities, or combined mechanisms not achievable through individual components. These engineered constructs typically join biologically active protein domains with Fc regions of antibodies extending circulation half-life, or complementary functional elements providing synergistic effects.

The pharmaceutical industry has developed numerous successful fusion protein therapeutics across diverse therapeutic areas. Fc fusion proteins represent the most common format, linking cytokine receptors, enzymes, or other bioactive proteins to antibody Fc regions, exemplified by etanercept combining TNF receptor with Fc for rheumatoid arthritis treatment. Extended half-life achieved through FcRn receptor recycling reduces dosing frequency improving patient compliance. Manufacturing requires optimising expression systems ensuring proper domain folding, developing purification strategies, and validating processes producing consistent fusion architectures. As protein engineering capabilities advance through computational design, directed evolution, and structural biology insights, fusion protein therapeutics continue diversifying addressing unmet medical needs.